Links for fulltext
     (May Require Subscription)
Supplementary

Article: Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial

TitleProtective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial
Authors
KeywordsInfluenza vaccine
2009 H1N1 influenza
Adolescent
Antibody titer
Child
Issue Date2012
PublisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2012, v. 55 n. 5, p. 695-702 How to Cite?
AbstractBACKGROUND: The efficacy of seasonal influenza vaccination against 2009 pandemic influenza A(H1N1) remains unclear. METHODS: One child aged 6-17 years in each of 796 households was randomized to receive 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV) or saline placebo between August 2009 and February 2010. Households were followed up with serology, symptom diaries, and collection of respiratory specimens during illnesses. The primary outcomes were influenza infection confirmed by reverse-transcription polymerase chain reaction (RT-PCR) or a >/=4-fold rise in serum antibody titer measured by hemagglutination inhibition assay. RESULTS: Receipt of TIV led to 8-13-fold mean geometric rises in antibody titers against seasonal A and B viruses, but only 1.5-fold mean geometric rises against the pandemic A(H1N1) virus that was not included in the vaccine. Children who received TIV had a reduced risk of seasonal influenza B confirmed by RT-PCR, with a vaccine efficacy estimate of 66% (95% confidence interval [CI], 31%-83%). Children who received TIV also a had reduced risk of pandemic influenza A(H1N1) indicated by serology, with a vaccine efficacy estimate of 47% (95% CI, 15%-67%). CONCLUSIONS: Seasonal TIV prevented pandemic influenza A(H1N1) and influenza B infections in children. Pandemic A(H1N1) circulated at the time of vaccination and for a short time afterward with no substantial seasonal influenza activity during that period. The potential mechanism for seasonal TIV to provide protection, possibly short lived, for children against pandemic A(H1N1) infection despite poor cross-reactive serologic response deserves further investigation. Clinical Trials Registration. NCT00792051.
Persistent Identifierhttp://hdl.handle.net/10722/166775
ISSN
2015 Impact Factor: 8.736
2015 SCImago Journal Rankings: 4.742
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCowling, BJen_HK
dc.contributor.authorNg, Sen_HK
dc.contributor.authorMa, ESKen_HK
dc.contributor.authorFang, VJen_HK
dc.contributor.authorSo, HCen_HK
dc.contributor.authorWai, Wen_HK
dc.contributor.authorCheng, CKYen_HK
dc.contributor.authorWong, JYen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorIp, DKMen_HK
dc.contributor.authorChiu, SSen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorLeung, GMen_HK
dc.date.accessioned2012-09-20T08:48:02Z-
dc.date.available2012-09-20T08:48:02Z-
dc.date.issued2012en_HK
dc.identifier.citationClinical Infectious Diseases, 2012, v. 55 n. 5, p. 695-702en_HK
dc.identifier.issn1058-4838en_HK
dc.identifier.urihttp://hdl.handle.net/10722/166775-
dc.description.abstractBACKGROUND: The efficacy of seasonal influenza vaccination against 2009 pandemic influenza A(H1N1) remains unclear. METHODS: One child aged 6-17 years in each of 796 households was randomized to receive 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV) or saline placebo between August 2009 and February 2010. Households were followed up with serology, symptom diaries, and collection of respiratory specimens during illnesses. The primary outcomes were influenza infection confirmed by reverse-transcription polymerase chain reaction (RT-PCR) or a >/=4-fold rise in serum antibody titer measured by hemagglutination inhibition assay. RESULTS: Receipt of TIV led to 8-13-fold mean geometric rises in antibody titers against seasonal A and B viruses, but only 1.5-fold mean geometric rises against the pandemic A(H1N1) virus that was not included in the vaccine. Children who received TIV had a reduced risk of seasonal influenza B confirmed by RT-PCR, with a vaccine efficacy estimate of 66% (95% confidence interval [CI], 31%-83%). Children who received TIV also a had reduced risk of pandemic influenza A(H1N1) indicated by serology, with a vaccine efficacy estimate of 47% (95% CI, 15%-67%). CONCLUSIONS: Seasonal TIV prevented pandemic influenza A(H1N1) and influenza B infections in children. Pandemic A(H1N1) circulated at the time of vaccination and for a short time afterward with no substantial seasonal influenza activity during that period. The potential mechanism for seasonal TIV to provide protection, possibly short lived, for children against pandemic A(H1N1) infection despite poor cross-reactive serologic response deserves further investigation. Clinical Trials Registration. NCT00792051.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/en_HK
dc.relation.ispartofClinical Infectious Diseasesen_HK
dc.rightsThis is a pre-copy-editing, author-produced PDF of an article accepted for publication in Clinical Infectious Diseases following peer review. The definitive publisher-authenticated version Clinical Infectious Diseases, 2012, v. 55 n. 5, p. 695-702 is available online at: http://cid.oxfordjournals.org/content/55/5/695-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectInfluenza vaccine-
dc.subject2009 H1N1 influenza-
dc.subjectAdolescent-
dc.subjectAntibody titer-
dc.subjectChild-
dc.titleProtective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.emailCowling, BJ: bcowling@hku.hken_HK
dc.identifier.emailFang, VJ: vickyf@hku.hken_HK
dc.identifier.emailSo, HC: haso9150@hku.hken_HK
dc.identifier.emailWai, W: bwskw01@hkucc.hku.hken_HK
dc.identifier.emailCheng, CKY: chengkyc@hkucc.hku.hken_HK
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hk-
dc.identifier.emailIp, DKM: dkmip@hku.hk-
dc.identifier.emailChiu, SS: ssschiu@hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.emailLeung, GM: gmleung@hku.hk-
dc.identifier.authorityCowling, BJ=rp01326en_HK
dc.identifier.authorityIp, DKM=rp00256en_HK
dc.identifier.authorityChiu, SS=rp00421en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.identifier.authorityLeung, GM=rp00460en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1093/cid/cis518en_HK
dc.identifier.pmid22670050-
dc.identifier.scopuseid_2-s2.0-84864940493en_HK
dc.identifier.hkuros206232en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84864940493&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume55en_HK
dc.identifier.issue5en_HK
dc.identifier.spage695en_HK
dc.identifier.epage702en_HK
dc.identifier.isiWOS:000307498300012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f1000717952622-
dc.identifier.scopusauthoridLeung, GM=7007159841en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridChiu, SS=7202291500en_HK
dc.identifier.scopusauthoridIp, DKM=35117701600en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridWong, JY=54390180800en_HK
dc.identifier.scopusauthoridCheng, CKY=24474272100en_HK
dc.identifier.scopusauthoridWai, W=35185575700en_HK
dc.identifier.scopusauthoridSo, HC=36172147200en_HK
dc.identifier.scopusauthoridFang, VJ=24474130400en_HK
dc.identifier.scopusauthoridMa, ESK=24725277400en_HK
dc.identifier.scopusauthoridNg, S=34977173400en_HK
dc.identifier.scopusauthoridCowling, BJ=8644765500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats